logo
  

Reata Pharma Stock Trading Halted As FDA Discusses Bardoxolone NDA - Quick Facts

Bopharmaceutical company Reata Pharmaceuticals, Inc. (RETA) announced Wednesday that Nasdaq has halted trading of the Company's common stock.

The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting to review the Company's New Drug Application (NDA) for bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome.

The Advisory Committee meeting is scheduled from 9:30 am to 5:00 pm ET today. The Prescription Drug User Fee Act date for completion of the review of the NDA for bardoxolone is February 25, 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Oilfield services company Schlumberger Ltd. reported Friday a profit for the fourth quarter that surged 61 percent from last year, reflecting 13 percent higher revenues amid growth across all segments and regions. Both adjusted earnings per share and quarterly revenues topped analysts' estimates. Twitter Inc. has launched a new feature to allow some users of its Blue subscriber service to keep non-fungible tokens or NFTs as their profile pictures. Twitter Blue is now available in the US, Canada, Australia, and New Zealand. NFT is a crypto token, which is non-fungible, meaning that it can neither be transferred like money nor replaced with something else. Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23.
RELATED NEWS
Follow RTT